MDX Meldex

    
  Meldex International PLC
  15 August 2008
   

 For Immediate Release  15 August 2008

    Meldex International plc (the 'Company')

    Launch of TabWrap* Menoflavon

    Meldex International plc (AIM:MDX) today announces the launch of a range of TabWrap* enabled Menoflavon products at the Expopharm
exhibition to be held in September 2008 in Munich. These new products will be made available at the Expo and thereafter launched in
pharmacies on an OTC basis throughout Austria and Germany.

    Expopharm has established itself internationally as the leading trade fair for the pharmacy sector as a platform for product launches,
news and developments in the pharmacy markets. Over the past few years, pharmacists from more than 50 different countries have attended
Expopharm in order to obtain and source new products and gather market data on current trends in the medical product market. 

    Over 25,000 specialist visitors, including German and international pharmacists are expected at the Expopharm this year. In addition to
the new Menoflavon range, Melbrosin will exhibit Menoflavon*, Melprotect*, Daosin* and some other product lines at Expopharm. 

    The Menoflavon range has been on the market since 2001 and is positioned as a natural alternative to HRT. The world HRT market is
believed to be close to USD 3.5 billion. (researchandmarkets.com/reports)



    For further information: 
 Meldex International Plc        + 44 (0) 20 7098 9880

 Buchanan Communications         + 44 (0) 20 7466 5000

 Nomura Code Securities Limited   + 44 (0) 20 776 1200

    About Meldex International
    Meldex International plc is an innovative specialty pharmaceutical and Over The Counter ('OTC') product company. Listed on London's AIM
in May 2003, Meldex has over 80patents granted or in business within 24 patent families and has product development agreements and strategic
alliances with several global healthcare companies.

    Meldex has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products.
Meldex acquired the Melbrosin business in June 2007 for a consideration of about EUR 23 million. Melbrosin's focus is on consumer OTC
healthcare products based on substances of natural and plant origin which are developed into consumer orientated brands then scaled,
produced and distributed by Melbrosin. Melbrosin complements the prescription pharmaceutical sales and marketing business created and
expanded in 2006.

    The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners
using its proprietary XGEL TM polymer technology.

    For further information please go to www.meldexinternational.com



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NRAIFFELTTISLIT

Meldex (LSE:MDX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Meldex (LSE:MDX)
Historical Stock Chart
From Jul 2023 to Jul 2024